T5O — bioXXmed AG Income Statement
0.000.00%
Last trade - 00:00- €0.29m
- €0.47m
- €0.02m
Annual income statement for bioXXmed AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | GAS | GAS | GAS | GAS | GAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.045 | 0.012 | 0.017 | 0.003 | 0.017 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.57 | 0.835 | 0.864 | 0.875 | 0.288 |
| Operating Profit | -1.53 | -0.823 | -0.846 | -0.872 | -0.271 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.02 | -0.83 | -21 | -0.997 | -0.365 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.06 | -0.83 | -20.9 | -0.997 | -0.365 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.06 | -0.83 | -20.9 | -0.997 | -0.365 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.06 | -0.83 | -20.9 | -0.997 | -0.365 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -40.1 | -6.62 | -167 | -3.67 | -6.72 |
| Dividends per Share |